Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997778794> ?p ?o ?g. }
- W2997778794 endingPage "813" @default.
- W2997778794 startingPage "804" @default.
- W2997778794 abstract "Abstract CD19-targeted immunotherapies have drastically improved outcomes for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) patients. Such therapies, including blinatumomab and CD19 chimeric antigen receptor (CD19CAR) T cells, yield high remission rates and can bridge to more definitive consolidation therapy with curative intent. Both treatments are approved by the US Food and Drug Administration (FDA) for r/r ALL (CD19CAR T-cell approval is restricted to patients ≤25 years old). Although availability of blinatumomab and CD19CAR T cells has extended options for the treatment of r/r ALL, prioritizing the sequence of these agents on an individual-patient basis may be difficult for the treating physician. Considering each therapy’s advantages, limitations, and challenges is necessary when choosing between them. Although patients may receive both blinatumomab and CD19CAR T cells sequentially in cases that fail to respond or subsequently relapse, a proportion of patients treated with CD19-targeted immunotherapy will lose expression of CD19 and will be excluded from receiving the alternative CD19-targeted therapy. Thus, weighing all considerations for each patient before selecting a CD19-targeted immunotherapy is crucial. Here, we discuss real-life scenarios of adults with r/r ALL, in which we selected either blinatumomab or CD19CAR T-cell therapy, and the rationale behind each decision." @default.
- W2997778794 created "2020-01-10" @default.
- W2997778794 creator A5039374832 @default.
- W2997778794 creator A5040369089 @default.
- W2997778794 date "2020-03-12" @default.
- W2997778794 modified "2023-09-29" @default.
- W2997778794 title "How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy" @default.
- W2997778794 cites W1754806051 @default.
- W2997778794 cites W1848034928 @default.
- W2997778794 cites W1967512987 @default.
- W2997778794 cites W1976187277 @default.
- W2997778794 cites W1977380325 @default.
- W2997778794 cites W1984079088 @default.
- W2997778794 cites W1988623079 @default.
- W2997778794 cites W2008009748 @default.
- W2997778794 cites W2031897049 @default.
- W2997778794 cites W203547899 @default.
- W2997778794 cites W2038702089 @default.
- W2997778794 cites W2107925822 @default.
- W2997778794 cites W2118241155 @default.
- W2997778794 cites W2118796952 @default.
- W2997778794 cites W2125259425 @default.
- W2997778794 cites W2129702476 @default.
- W2997778794 cites W2141019574 @default.
- W2997778794 cites W2179454156 @default.
- W2997778794 cites W2265134611 @default.
- W2997778794 cites W2277505199 @default.
- W2997778794 cites W2342423058 @default.
- W2997778794 cites W2346378690 @default.
- W2997778794 cites W2400439118 @default.
- W2997778794 cites W2419639370 @default.
- W2997778794 cites W2496398835 @default.
- W2997778794 cites W2514418134 @default.
- W2997778794 cites W2516611622 @default.
- W2997778794 cites W2529226476 @default.
- W2997778794 cites W2576962736 @default.
- W2997778794 cites W2591709377 @default.
- W2997778794 cites W2599899418 @default.
- W2997778794 cites W2606654718 @default.
- W2997778794 cites W2611189127 @default.
- W2997778794 cites W2613659662 @default.
- W2997778794 cites W2614019261 @default.
- W2997778794 cites W2653911491 @default.
- W2997778794 cites W2662598785 @default.
- W2997778794 cites W2748768234 @default.
- W2997778794 cites W2761529444 @default.
- W2997778794 cites W2768556518 @default.
- W2997778794 cites W2768823259 @default.
- W2997778794 cites W2787145330 @default.
- W2997778794 cites W2787301955 @default.
- W2997778794 cites W2787621143 @default.
- W2997778794 cites W2792216594 @default.
- W2997778794 cites W2807514643 @default.
- W2997778794 cites W2888019042 @default.
- W2997778794 cites W2891253541 @default.
- W2997778794 cites W2892758519 @default.
- W2997778794 cites W2900726364 @default.
- W2997778794 cites W2905654455 @default.
- W2997778794 cites W2905858534 @default.
- W2997778794 cites W2908231438 @default.
- W2997778794 cites W2908240709 @default.
- W2997778794 cites W2911254867 @default.
- W2997778794 cites W2911504656 @default.
- W2997778794 cites W2913985417 @default.
- W2997778794 cites W2914373601 @default.
- W2997778794 cites W2914847624 @default.
- W2997778794 cites W2915721177 @default.
- W2997778794 cites W2919881382 @default.
- W2997778794 cites W2937212509 @default.
- W2997778794 cites W2971361007 @default.
- W2997778794 cites W2975666914 @default.
- W2997778794 doi "https://doi.org/10.1182/blood.2019002132" @default.
- W2997778794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31899793" @default.
- W2997778794 hasPublicationYear "2020" @default.
- W2997778794 type Work @default.
- W2997778794 sameAs 2997778794 @default.
- W2997778794 citedByCount "32" @default.
- W2997778794 countsByYear W29977787942015 @default.
- W2997778794 countsByYear W29977787942020 @default.
- W2997778794 countsByYear W29977787942021 @default.
- W2997778794 countsByYear W29977787942022 @default.
- W2997778794 countsByYear W29977787942023 @default.
- W2997778794 crossrefType "journal-article" @default.
- W2997778794 hasAuthorship W2997778794A5039374832 @default.
- W2997778794 hasAuthorship W2997778794A5040369089 @default.
- W2997778794 hasBestOaLocation W29977787941 @default.
- W2997778794 hasConcept C121608353 @default.
- W2997778794 hasConcept C126322002 @default.
- W2997778794 hasConcept C143998085 @default.
- W2997778794 hasConcept C147483822 @default.
- W2997778794 hasConcept C203014093 @default.
- W2997778794 hasConcept C2777701055 @default.
- W2997778794 hasConcept C2778020697 @default.
- W2997778794 hasConcept C2778461978 @default.
- W2997778794 hasConcept C2778957590 @default.
- W2997778794 hasConcept C2781107101 @default.
- W2997778794 hasConcept C2909962599 @default.
- W2997778794 hasConcept C3875195 @default.